Articular cartilage nuclear receptors: an emerging target for treatment of osteoarthritis  by Loeser, R.F.
Osteoarthritis and Cartilage (2009) 17, 829e831
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2009.03.025
International
Cartilage
Repair
SocietyEditorial
Articular cartilage nuclear receptors: an emerging target for treatment of
osteoarthritis
R. F. Loeser*
Department of Internal Medicine, Section of Molecular Medicine, Wake Forest University School of Medicine,
Winston-Salem, NC 27157, USA
Key words: Cartilage, Osteoarthritis, Nuclear receptors, Therapy.A major focus of translational research in osteoarthritis (OA)
is discovery of the factors that regulate articular cartilage
homeostasis. The hope of many investigators, and patients
alike, is that new insights into the regulation of cartilage me-
tabolism will lead to the development of therapeutic agents
that will slow or halt the progression of cartilage destruction
in OA. There is substantial evidence that an imbalance in
anabolic and catabolic activity in cartilage, favoring catabo-
lism of the extracellular matrix, plays a central role in the
loss of cartilage that is characteristic of OA1,2. It might be
debated whether targeting cartilage metabolism will affect
progression of a disease that involves altered biomechanics
and affects multiple joint tissues in addition to cartilage.
However, until we have clinical trial evidence to suggest
otherwise, articular cartilage metabolism will continue to
be a major therapeutic target.
The articular chondrocytes, which are responsible for
both synthesis and degradation of the cartilage matrix,
are regulated by a host of signals generated by growth
factors, cytokines/chemokines, changes in the extracellular
matrix, and mechanical stimulation1,2. A multitude of sig-
naling pathways, activated by these diverse stimuli, act
in concert to regulate chondrocyte expression and synthe-
sis of matrix proteins as well as enzymes that degrade
matrix proteins. The signaling pathways that regulate
chondrocyte matrix synthesis and degradation represent
potential therapeutic targets. Limited pre-clinical studies
in animal models have provided proof of concept for a pos-
itive effect on articular cartilage with inhibition of certain
cell signaling proteins, such as the mitogen-activated pro-
tein kinases, that are central to multiple pathways3. How-
ever, speciﬁcity of small molecule inhibitors of cell
signaling proteins and toxicity related to off target effects
have been a concern.
Another approach to modulating intracellular signaling
pathways that regulate gene expression is to target nuclear
receptors. Nuclear receptors bind a large number of ligands
to mediate a diverse array of cellular responses generated
by hormonal and metabolic signals. Nuclear receptors act
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829contain certain conserved structural domains that mediate
ligand binding, binding to DNA, and binding to regulatory
co-factors including other nuclear receptors and transcrip-
tion factors4. There are 48 known human nuclear receptors
that function as homo-and/or heterodimers or less com-
monly as monomers5.
Nuclear receptors bind to a diverse group of ligands that
include lipids such as fatty acids ( peroxisome proliferator-
activated receptors, PPARs) and cholesterol metabolites
(liver X receptor, LXR), fat soluble vitamins (vitamin D
receptor, VDR; retinoic acid receptor, RAR), hormones
such as estrogen (estrogen receptors, ER), steroids
( glucocorticoid receptor, GR) and thyroid hormone (thyroid
hormone receptor, TR), and xenobiotics ( pregnane X re-
ceptor, PXR also called steroid and xenobiotic sensor,
SXR). Because the retinoid X receptor (RXR) forms hetero-
dimers with several different nuclear receptors and regu-
lates multiple signaling pathways it is often called
a ‘‘master regulator’’. Approximately half the members of
the nuclear receptor family do not have a known ligand
and are often termed ‘‘orphan receptors’’ ( for example
Nur-related factor 1, NURR1)4.
Nuclear receptors are considered by the pharmaceutical
industry to be good drug targets. Ligands for the nuclear re-
ceptors in the endocrine subfamily, such as thyroid hor-
mone, various steroid hormones, vitamins A and D, and
estrogen, are widely used for a number of conditions and
some are potential therapies for OA. Due to evidence sug-
gesting increased progression of knee OA in people with
low serum levels of vitamin D6 and the well documented ef-
fects of vitamin D on bone, there are two ongoing clinical tri-
als (listed on clinicaltrials.gov) examining the ability of
vitamin D to slow progression of knee OA. There is evi-
dence, although not conclusive, that postmenopausal estro-
gen loss may contribute to the progression of OA in women
and, at least in animal models, estrogen replacement ther-
apy initiated at the time of surgically induced menopause
can slow disease progression7,8.
The PPARs have received much attention as therapeutic
targets. Successful drugs to date include the thiazolidine-
diones for type II diabetes that activate PPARg and serve
as insulin-sensitizers and the ﬁbrates that activate PPARa
to lower serum lipids. Given their important functions as inte-
grators of metabolic and inﬂammatory signaling pathways9,
PPARs as well as LXRs could represent therapeutic targets
in OA. In vitro studies have suggested that agonists of
830 R. F. Loeser: Articular cartilage nuclear receptorsPPARg have an anti-catabolic effect in articular cartilage,
supporting their potential use as disease-modifying drugs
for OA10,11. Indeed, animal model studies have demon-
strated that the PPARg agonist pioglitazone can reduce pro-
gression of surgically induced OA in guinea pigs12 and
dogs13 but trials in humans are not yet available.
Looking for additional nuclear receptor targets in OA, Col-
lins-Racie and colleagues report, in this issue ofOsteoarthri-
tis and Cartilage, an analysis of the expression of all known
nuclear receptors in both normal and osteoarthritic human ar-
ticular cartilage14. Out of the 48 known nuclear receptors, 31
were surprisingly found to be expressed at detectable levels
in cartilage. Expression of 23 nuclear receptors was signiﬁ-
cantly different between RNA samples isolated from normal
and OA cartilage. Most of the nuclear receptors identiﬁed in
cartilage were downregulated in OA tissue relative to normal
tissue with the exception of RARb andRARgwhich were sig-
niﬁcantly upregulated. Given the potential for increased RAR
activity to down-regulate cartilage matrix gene expression15,
the ﬁnding of increased RAR in OA cartilage might be func-
tionally signiﬁcant.
An interesting technical ﬁnding from the analysis was that
all but four of the nuclear receptors (Rev-Erba, LXRb,
RXRa, and GR) were expressed at levels below the detec-
tion limits of standard microarray analysis using Affymetrix
GeneChips. The remaining 27 were detected using
a more sensitive custom TaqMan real-time polymerase
chain reaction (PCR) array. This ﬁnding supports the con-
cept that important genes can be missed when relying
only on standard microarrays for initial screening of gene
expression. However, the signiﬁcance of detecting RNA
coding for the 31 nuclear receptors in chondrocytes using
a sensitive real-time PCR expression analysis will not be
known until further experiments are performed. It will be im-
portant to determine which of these nuclear receptors are
present at the protein level and which are functional in
chondrocytes.
There is data, albeit limited, in the prior literature and in
the new results presented by Collins-Racie et al. to suggest
that at least some of the nuclear receptors identiﬁed in this
study are functional in cartilage. Besides the previous work
noted above on PPARg and ERa and ERb, the orphan nu-
clear receptor NURR1 has been previously identiﬁed in hu-
man articular cartilage where overexpression of NURR1 by
transient transfection was found to repress expression of
matrix metalloproteinase (MMP)-1, -3, and -916. Contrary
to the results of Collins-Racie et al. which found no signiﬁ-
cant difference in NURR1 expression between normal and
OA, the previous study by Mix et al. noted a signiﬁcant in-
crease in OA tissue, although this result appeared to be
driven by a few high expressors. Others have provided ev-
idence in chondrocytes for functional VDR and RXR17,18,
Rev-ErbAa19, RAR15 and in growth plate chondrocytes
RAR-related orphan receptor (ROR)a20.
Collins-Racie et al. chose to focus additional experi-
ments on LXRa and LXRb which were signiﬁcantly de-
creased in OA relative to normal cartilage. Decreased
expression of three known LXR target genes was also
noted in OA cartilage adding support to functional signiﬁ-
cance. Importantly, addition of a synthetic LXR agonist
(TO901317) stimulated expression of the LXR target genes
in OA cells and inhibited proteoglycan release (as a mea-
sure of proteoglycan degradation) from OA cartilage ex-
plants as well as explants treated with the cytokines
interleukin-1 and oncostatin M. The LXR agonist also
caused expression of LXR itself to increase in a positive
feedback manner suggesting that the use of such anagonist could restore normal levels of LXR in OA cells
and potentially inhibit proteoglycan degradation.
The imbalance in anabolic and catabolic activities in car-
tilage that is characteristic of OA appears to be driven by an
increase in levels of numerous inﬂammatory mediators in-
cluding cytokines, chemokines, prostaglandins, leukotri-
enes, and reactive oxygen species, among others1,2.
Targeting these factors separately will be difﬁcult and at-
tempts to do so have not met with much success. Given
the knowledge that activation of several of the nuclear re-
ceptor family members including PPARg, LXR, RXR, ER,
and NURR1 can have anti-inﬂammatory and/or anti-cata-
bolic effects, and given the relative safety proﬁle of nuclear
receptor agonists studied to date, we may expect an emer-
gence of new therapies targeting nuclear receptors in OA.
Clearly, further work is indicated to determine the nuclear
receptors that would be the best targets in OA but the study
by Collins-Racie et al. sheds light on where further efforts
may lead.Conﬂict of interest
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